97 related articles for article (PubMed ID: 7706130)
21. Synthesis and biological evaluation of cytogenin derivatives.
Matsumoto N; Nakashima T; Isshiki K; Kuboki H; Hirano SI; Kumagai H; Yoshioka T; Ishizuka M; Takeuchi T
J Antibiot (Tokyo); 2001 Mar; 54(3):285-96. PubMed ID: 11372785
[TBL] [Abstract][Full Text] [Related]
22. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A.
Quintieri L; Rosato A; Napoli E; Sola F; Geroni C; Floreani M; Zanovello P
Cancer Res; 2000 Jun; 60(12):3232-8. PubMed ID: 10866316
[TBL] [Abstract][Full Text] [Related]
23. In vivo efficacy of novel synthetic enediynes 1.
Wrasidlo W; Hiatt A; Mauch S; Merlock RA; Nicolaou KC
Acta Oncol; 1995; 34(2):157-64. PubMed ID: 7718252
[TBL] [Abstract][Full Text] [Related]
24. Antitumor activity and novel DNA-self-strand-breaking mechanism of CNDAC (1-(2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl) cytosine) and its N4-palmitoyl derivative (CS-682).
Hanaoka K; Suzuki M; Kobayashi T; Tanzawa F; Tanaka K; Shibayama T; Miura S; Ikeda T; Iwabuchi H; Nakagawa A; Mitsuhashi Y; Hisaoka M; Kaneko M; Tomida A; Wataya Y; Nomura T; Sasaki T; Matsuda A; Tsuruo T; Kurakata S
Int J Cancer; 1999 Jul; 82(2):226-36. PubMed ID: 10389757
[TBL] [Abstract][Full Text] [Related]
25. Action of cytogenin on lymphoid cells and their cytokine production.
Kumagai H; Osono M; Iijima M; Sakashita M; Ishizuka M; Takeuchi T
J Antibiot (Tokyo); 1995 Apr; 48(4):317-20. PubMed ID: 7775269
[TBL] [Abstract][Full Text] [Related]
26. [Antitumor activity of yungumycin].
Xue YC; Wu SY; Li Y; Zhang SH; Zhen YS
Yao Xue Xue Bao; 1996; 31(3):171-5. PubMed ID: 9206265
[TBL] [Abstract][Full Text] [Related]
27. Selective depletion of NK cell activity in vivo and its effect on the growth of NK-sensitive and NK-resistant tumor cell variants.
Kawase I; Urdal DL; Brooks CG; Henney CS
Int J Cancer; 1982 May; 29(5):567-74. PubMed ID: 7095901
[TBL] [Abstract][Full Text] [Related]
28. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and antitumor activity of duocarmycin derivatives: modification of segment A of duocarmycin B2.
Nagamura S; Asai A; Kanda Y; Kobayashi E; Gomi K; Saito H
Chem Pharm Bull (Tokyo); 1996 Sep; 44(9):1723-30. PubMed ID: 8855367
[TBL] [Abstract][Full Text] [Related]
30. The antitumor activity of doxorubicin against drug-resistant murine carcinoma is enhanced by oral administration of a synthetic staurosporine analogue, CGP 41251.
Killion JJ; Beltran P; O'Brian CA; Yoon SS; Fan D; Wilson MR; Fidler IJ
Oncol Res; 1995; 7(9):453-9. PubMed ID: 8835289
[TBL] [Abstract][Full Text] [Related]
31. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
[TBL] [Abstract][Full Text] [Related]
32. Antitumor effects of oral administration of an interferon-inducing pyrimidinone, Bropirimine, on murine renal-cell carcinoma.
Fujioka T; Ishikura K; Hasegawa M; Ogyu K; Matsushita Y; Sato M; Sato F; Aoki H; Kubo T
Cancer Chemother Pharmacol; 1995; 36(1):7-12. PubMed ID: 7536641
[TBL] [Abstract][Full Text] [Related]
33. Antitumor activity of a novel antitumor antibiotic, quinocarmycin citrate (KW2152).
Fujimoto K; Oka T; Morimoto M
Cancer Res; 1987 Mar; 47(6):1516-22. PubMed ID: 2434218
[TBL] [Abstract][Full Text] [Related]
34. Therapy for mouse tumors and human tumor xenografts with the antitumor antibiotic AT-125.
Houchens DP; Ovejera AA; Sheridan MA; Johnson RK; Bogden AE; Neil GL
Cancer Treat Rep; 1979 Mar; 63(3):473-6. PubMed ID: 427827
[TBL] [Abstract][Full Text] [Related]
35. Antitumor activity of SPM VIII, a derivative of the nucleoside antibiotic spicamycin, against human tumor xenografts.
Kamishohara M; Kawai H; Odagawa A; Isoe T; Mochizuki J; Uchida T; Hayakawa Y; Seto H; Tsuruo T; Otake N
J Antibiot (Tokyo); 1994 Nov; 47(11):1305-11. PubMed ID: 8002395
[TBL] [Abstract][Full Text] [Related]
36. [Antitumor activity of HO-221, a derivative of benzoylphenylurea against human cancer xenografts in nude mice].
Fujita F; Fujita M; Inaba H; Sugimoto T; Okuyama Y; Taguchi T
Gan To Kagaku Ryoho; 1991 Oct; 18(13):2255-61. PubMed ID: 1929446
[TBL] [Abstract][Full Text] [Related]
37. Effect of bestatin on syngeneic tumors in mice.
Abe F; Shibuya K; Uchida M; Takahashi K; Horinishi H; Matsuda A; Ishizuka M; Takeuchi T; Umezawa H
Gan; 1984 Jan; 75(1):89-94. PubMed ID: 6586596
[TBL] [Abstract][Full Text] [Related]
38. Antitumor spectrum of deoxyspergualin and its lack of cross-resistance to other antitumor agents.
Nishikawa K; Shibasaki C; Hiratsuka M; Arakawa M; Takahashi K; Takeuchi T
J Antibiot (Tokyo); 1991 Oct; 44(10):1101-9. PubMed ID: 1955393
[TBL] [Abstract][Full Text] [Related]
39. Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts.
Morisada S; Yanagi Y; Noguchi T; Kashiwazaki Y; Fukui M
Jpn J Cancer Res; 1989 Jan; 80(1):69-76. PubMed ID: 2496061
[TBL] [Abstract][Full Text] [Related]
40. Antitumor activity of a new antitumor antibiotic, stubomycin.
Komiyama K; Edanami K; Yamamoto H; Umezawa I
J Antibiot (Tokyo); 1982 Jun; 35(6):703-6. PubMed ID: 7118726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
